No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Allogene Granted 3 U.S. FDA Fast Track Designations For ALLO-329 For The Treatment Of Lupus, Myositis And Scleroderma
Express News | Allogene Therapeutics Inc: Expects to Initiate Phase 1 Resolution Basket Trial in Mid-2025
Express News | Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) for Allo-329, a Next-Generation Dual-Targeted Cd19/Cd70 Allogeneic Car T, for the Treatment of Lupus, Myositis and Scleroderma
H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Cuts Target Price to $8
Allogene Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Allogene Therapeutics (ALLO) Receives a Buy From Oppenheimer
